The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors
Open accessAbstract
Cyclin-dependent kinases 12 and 13 (CDK12 and 13) play critical roles in the regulation of gene transcription. However, the absence of CDK12 and 13 inhibitors has hindered the ability to investigate the consequences of their inhibition in healthy cells and cancer cells. Here we describe the rational design of a first-in-class CDK12 and 13 covalent inhibitor, THZ531. Co-crystallization with CDK12-cyclin K indicates that THZ531 irreversibly targets a cysteine located outside the kinase domain. THZ531 causes a loss of gene expression with concurrent loss of elongating and hyperphosphorylated RNA polymerase II. In particular, THZ531 substantially decreases the expression of DNA damage response genes and key super–enhancer–associated transcription factor genes. Coincident with transcriptional perturbation, THZ531 dramatically induced apoptotic cell death. Small molecules capable of specifically targeting CDK12 and 13 may thus help identify cancer subtypes that are particularly dependent on their kinase activities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“THZ53124, a bulky covalent CDK12/13 inhibitor predicted to clash with DDB1 (Extended Data Fig. 6d–f), locks the CDK12 C-terminal extension in a conformation incompatible with DDB1 recruitment (Extended Data Fig. 6d).”
From The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K (2020) · cites this paper as [24]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Consistently, THZ531 further decreased the TR-FRET signal and diminished cycK ubiquitination in vitro below DMSO control levels (Fig. 3d, Extended Data Fig. 6c, f)24.”
From The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K (2020) · cites this paper as [24]
Experimental — accuracy not yet measuredIn the citing paper
“THZ531, a CDK12-CDK13 covalent inhibitor, binds with CDK12-cyclin K via a cysteine residue that is located outside the kinase domain [97].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [97]
In the citing paper
“Furthermore, THZ531 induced cell death and apoptosis in Ewing sarcoma cancer cell lines.”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [97]
In the citing paper
“Consistent with this notion, HQ461-mediated depletion of Cyclin K phenotypically mimics dual inhibition of CDK12 and CDK13 by the CDK12/13-selective inhibitor THZ531 to trigger cell death (Zhang et al., 2016).”
From Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation (2020) · cites this paper as Zhang et al., 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.
Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn923 · Cited by 14,108
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197
REFMAC 5 for the refinement of macromolecular crystal structures
Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., Winn, M., Long, F., & Vagin, A. A. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911001314 · Cited by 8,415
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 396
Super-Enhancers, Phase-Separated Condensates, and 3D Genome Organization in Cancer
Tang, S. C., Vijayakumar, U., Zhang, Y., & Fullwood, M. J. (2022) · Cancers · doi:10.3390/cancers14122866 · Cited by 56
Advances of small molecule targeting of kinases
Berndt, N., Karim, R. M., & Schönbrunn, E. (2017) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2017.06.015 · Cited by 56
Structure-based discovery of cyclin-dependent protein kinase inhibitors
Martin, M. P., Endicott, J., & Noble, M. E. M. (2017) · Essays in Biochemistry · doi:10.1042/ebc20170040 · Cited by 53
Therapeutic Targeting of the General RNA Polymerase II Transcription Machinery
Martin, R., Hébert, T. E., & Tanny, J. C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093354 · Cited by 51
Recent Advances in CDK Inhibitors for Cancer Therapy
Heptinstall, A. B., Adiyasa, I., Cano, C., & Hardcastle, I. R. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0246 · Cited by 52
Cesari, E., Ciucci, A., Pieraccioli, M., Caggiano, C., Nero, C., Bonvissuto, D., Sillano, F., Buttarelli, M., Piermattei, A., Loverro, M., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02682-5 · Cited by 51
Houles, T., Boucher, J., Lavoie, G., MacLeod, G., Lin, S., Angers, S., & Roux, P. P. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01754-x · Cited by 49
Emerging Implications of Phase Separation in Cancer
Ren, J., Zhang, Z., Zong, Z., Zhang, L., & Zhou, F. (2022) · Advanced Science · doi:10.1002/advs.202202855 · Cited by 48
Ex vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcoma
Bayles, I., Krajewska, M., Pontius, W. D., Saiakhova, A., Morrow, J. J., Bartels, C., Lu, J., Faber, Z. J., Fedorov, Y., Hong, E. S., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127718 · Cited by 46
Filippone, M. G., Gaglio, D., Bonfanti, R., Tucci, F. A., Ceccacci, E., Pennisi, R., Bonanomi, M., Jodice, G., Tillhon, M., Montani, F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30375-8 · Cited by 46
High-resolution cryo-EM of the human CDK-activating kinase for structure-based drug design
Cushing, V. I., Koh, F., Feng, J., Jurgaityte, K., Bondke, A., Kroll, S. H. B., Barbazanges, M., Scheiper, B., Bahl, A. K., Barrett, A. G. M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46375-9 · Cited by 46
CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancer
Lei, H., Wang, Z., Jiang, D., Liu, F., Liu, M., Lei, X., Yang, Y., He, B., Yan, M., Huang, H. W., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04027-6 · Cited by 47
Bhurta, D., & Bharate, S. B. (2021) · Medicinal Research Reviews · doi:10.1002/med.21856 · Cited by 47
Zheng, L., Liu, C., & Yu, K. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01522-5 · Cited by 50
Zhang, Y., Zhou, L., Bandyopadhyay, D., Sharma, K., Allen, A. J., Kmieciak, M., & Grant, S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3788 · Cited by 45
Schecher, S., Walter, B., Falkenstein, M., Macher‐Goeppinger, S., Stenzel, P., Krümpelmann, K., Hadaschik, B. A., Perner, S., Kristiansen, G., Duensing, S. M., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30864 · Cited by 45
Transcription associated cyclin-dependent kinases as therapeutic targets for prostate cancer
Constantin, T. A., Greenland, K. K., Varela‐Carver, A., & Bevan, C. L. (2022) · Oncogene · doi:10.1038/s41388-022-02347-1 · Cited by 46
Tien, J. C.-Y., Luo, J., Chang, Y., Zhang, Y., Cheng, Y., Wang, X., Yang, J., Mannan, R., Mahapatra, S., Shah, P., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101758 · Cited by 45
CDK12: cellular functions and therapeutic potential of versatile player in cancer
Pilařová, K., Herudek, J., & Blažek, D. (2020) · NAR Cancer · doi:10.1093/narcan/zcaa003 · Cited by 43
Advanced approaches of developing targeted covalent drugs
Gai, C., Harnor, S. J., Zhang, S., Cano, C., Zhuang, C., & Zhao, Q. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00216g · Cited by 44
Choi, S. H., Kim, S., & Jones, K. A. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0442-9 · Cited by 43
CDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanoma
Houlès, T., Lavoie, G., Nourreddine, S., Cheung, W., Vaillancourt-Jean, É., Guérin, C. M., Bouttier, M., Grondin, B., Lin, S., Saba-El-Leil, M. K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34179-8 · Cited by 46
Sterling, J., Baker, J. R., McCluskey, A., & Munoz, L. (2023) · Nature Communications · doi:10.1038/s41467-023-38952-1 · Cited by 40
Henry, K. L., Kellner, D., Bajrami, B., Anderson, J. E., Beyna, M., Bhisetti, G., Cameron, T. O., Capacci, A. G., Bertolotti‐Ciarlet, A., Feng, J., et al. (2018) · Science Signaling · doi:10.1126/scisignal.aam8216 · Cited by 40
Liquid‒liquid phase separation: roles and implications in future cancer treatment
Liu, Z., Qin, Z., Liu, Y., Xia, X., He, L., Chen, N., Hu, X., & Peng, X. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.81521 · Cited by 38
Ficarro, S. B., Browne, C. M., Card, J. D., Alexander, W. M., Zhang, T., Park, E., McNally, R., Dhe‐Paganon, S., Seo, H., Lamberto, I., et al. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b03394 · Cited by 36
Self-citationThe PAF1 complex promotes 3′ processing of pervasive transcripts
Liu, X., Guo, Z., Han, J., Peng, B., Zhang, B., Li, H., Hu, X., David, C. J., & Chen, M. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110519 · Cited by 36
Sun, J., Zhong, H., Wang, K., Li, N., & Chen, L. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.02.023 · Cited by 39
Covalent chemical probes for protein kinases
Serafim, R. A. M., Haarer, L., Pedreira, J. G. B., & Gehringer, M. (2023) · Current Research in Chemical Biology · doi:10.1016/j.crchbi.2022.100040 · Cited by 34
Qiu, M., Yin, Z., Wang, H., Lei, L., Li, C., Cui, Y., Dai, R., Yang, P., Xiang, Y., Li, Q., et al. (2023) · Science Advances · doi:10.1126/sciadv.adf8698 · Cited by 40
CDK12: a potential therapeutic target in cancer
Emadi, F., Teo, T., Rahaman, M. H., & Wang, S. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.09.035 · Cited by 36
Transcriptional cyclin-dependent kinases: Potential drug targets in cancer therapy
Liu, Y., Fu, L., Wu, J., Liu, M., Wang, G., Liu, B., & Zhang, L. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114056 · Cited by 38
BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitors
Paculová, H., Kramara, J., Šimečková, Š., Fedr, R., Souček, K., Hylse, O., Paruch, K., Svoboda, M., Mistrík, M., & Kohoutek, J. (2017) · Tumor Biology · doi:10.1177/1010428317727479 · Cited by 34
Targeting CDK12-mediated transcription regulation in anaplastic thyroid carcinoma
Geng, M., Yang, Y., Cao, X., Dang, L., Zhang, T., & Zhang, L. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.10.052 · Cited by 34
Self-citationShan, W., Yuan, J., Hu, Z., Jiang, J., Wang, Y., Loo, N., Fan, L., Tang, Z., Zhang, T., Xu, M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107884 · Cited by 35
Self-citationTargeting CDK7 in oncology: The avenue forward
Li, Z., Liu, G., Gao, Y., & Zhao, M. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108229 · Cited by 34
Panzeri, V., Pieraccioli, M., Cesari, E., de la Grange, P., & Sette, C. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad258 · Cited by 35
Discovery of Covalent CDK14 Inhibitors with Pan-TAIRE Family Specificity
Ferguson, F. M., Doctor, Z. M., Ficarro, S. B., Browne, C. M., Marto, J. A., Johnson, J. L., Yaron, T. M., Cantley, L. C., Kim, N. D., Sim, T., et al. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.02.015 · Cited by 31
Self-citationChemical Probes for Understudied Kinases: Challenges and Opportunities
Serafim, R. A. M., Elkins, J. M., Zuercher, W. J., Laufer, S., & Gehringer, M. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00980 · Cited by 32
Self-citationSuper-enhancers and novel therapeutic targets in colorectal cancer
Liu, Q., Guo, L., Lou, Z., Xiang, X., & Shao, J. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04673-4 · Cited by 31
Effects of super-enhancers in cancer metastasis: mechanisms and therapeutic targets
Liu, S., Dai, W., Jin, B., Jiang, F., Huang, H., Hou, W., Lan, J., Jin, Y., Peng, W., & Pan, J. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02033-8 · Cited by 35
SOX17 and PAX8 constitute an actionable lineage-survival transcriptional complex in ovarian cancer
Lin, L., Shi, K., Zhou, S., Cai, M., Zhang, C., Sun, Y., Zang, J., Cheng, L., Ye, K., Ma, P., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02210-3 · Cited by 31
Zhang, L., Zhen, Y., Lu, F., Li, Z., Lü, Y., Wang, G., & Ouyang, L. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115648 · Cited by 31
Chatterboxes: the structural and functional diversity of cyclins
Tatum, N. J., & Endicott, J. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.04.021 · Cited by 27
Dysregulated Transcriptional Control in Prostate Cancer
Baumgart, S. J., Nevedomskaya, E., & Haendler, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20122883 · Cited by 30
Chemical inhibitors of transcription-associated kinases
Clopper, K. C., & Taatjes, D. J. (2022) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2022.102186 · Cited by 31
Covalent hits and where to find them
Lucas, S. C. C., Blackwell, J. H., Hewitt, S. H., Semple, H., Whitehurst, B. C., & Xu, H. (2024) · SLAS DISCOVERY · doi:10.1016/j.slasd.2024.01.003 · Cited by 30
Kurinna, S. M., Seltmann, K., Bachmann, A., Schwendimann, A., Thiagarajan, L., Hennig, P., Beer, H., Mollo, M. R., Missero, C., & Werner, S. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab167 · Cited by 25
Zhu, H., Ficarro, S. B., Alexander, W. M., Fleming, L. E., Adelmant, G., Zhang, T., Willetts, M., Decker, J., Brehmer, S., Krause, M., et al. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c02349 · Cited by 30
Self-citationCDK12 regulates co-transcriptional splicing and RNA turnover in human cells
Magnuson, B., Bedi, K., Narayanan, I. V., Bartkowiak, B., Blinkiewicz, H., Paulsen, M. T., Greenleaf, A. L., & Ljungman, M. E. (2022) · iScience · doi:10.1016/j.isci.2022.105030 · Cited by 32
Self-citationDai, W., Wu, J., Peng, X., Hou, W., Huang, H., Cheng, Q., Liu, Z., Luyten, W., Schoofs, L., Zhou, J., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.1087 · Cited by 28
Therapeutic targeting of CPSF3-dependent transcriptional termination in ovarian cancer
Shen, P., Ye, K., Xiang, H., Zhang, Z., He, Q., Zhang, X., Cai, M., Chen, J., Sun, Y., Lin, L., et al. (2023) · Science Advances · doi:10.1126/sciadv.adj0123 · Cited by 25
Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors
Chou, J., Robinson, T. M., Egusa, E. A., Lodha, R., Zhang, M., Badura, M. L., Mikayelyan, M., Delavan, H. M., Swinderman, J. T., Wilson, C., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3785 · Cited by 28
Omar, H. A., & Tolba, M. F. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.01.009 · Cited by 28
Innovative design and potential applications of covalent strategy in drug discovery
Tang, T., Luo, J., Zhang, D., Lü, Y., Liao, W., & Zhang, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117202 · Cited by 27
Current progress and novel strategies that target CDK12 for drug discovery
Lei, P., Zhang, J., Liao, P., Ren, C., Wang, J., & Wang, D. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114603 · Cited by 26
Structure–Activity Relationship Study of QL47: A Broad-Spectrum Antiviral Agent
Liang, Y., de Wispelaere, M., Carocci, M., Liu, Q., Wang, J., Yang, P. L., & Gray, N. S. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00008 · Cited by 28
Self-citationDiscovery of ZLC491 as a Potent, Selective, and Orally Bioavailable CDK12/13 PROTAC Degrader
Zhou, L., Zhou, K., Chang, Y., Yang, J., Fan, B., Su, Y., Li, Z., Mannan, R., Mahapatra, S., Ding, M., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01596 · Cited by 26
Cyclin-dependent kinases-based synthetic lethality: Evidence, concept, and strategy
Li, K., You, J., Wu, Q., Meng, W., He, Q., Yang, B. R., Zhu, C., & Cao, J. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.01.002 · Cited by 26
Saramago, L., Santana, M. V., Gomes, B. F., Dantas, R. F., Senger, M. R., Borges, P. H. O., Ferreira, V. N. D. S., Rosa, A. D. S., Tucci, A. R., Miranda, M. D., et al. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00409 · Cited by 25
Recent advances in dual PROTACs degrader strategies for disease treatment
Liu, J., Liu, Y., Tang, J., Gong, Q., Yan, G., Fan, H., Zhang, X., & Pu, C. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116901 · Cited by 25
Advances in reversible covalent kinase inhibitors
Zhao, Z., & Bourne, P. E. (2024) · Medicinal Research Reviews · doi:10.1002/med.22084 · Cited by 26
Chang, Y., Wang, X., Yang, J., Tien, J. C.-Y., Mannan, R., Cruz, G., Zhang, Y., Vo, J. N., Magnuson, B., Mahapatra, S., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101752 · Cited by 24
Cacioppo, R., Gillis, A., Shlamovitz, I., Zeller, A., Castiblanco, D., Crisp, A., Haworth, B., Arabiotorre, A., Abyaneh, P., Bao, Y., et al. (2024) · Molecular Cell · doi:10.1016/j.molcel.2024.11.024 · Cited by 26
Recent progress in development of cyclin-dependent kinase 7 inhibitors for cancer therapy
Liang, H., Du, J., Elhassan, R. M., Hou, X., & Fang, H. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1850693 · Cited by 23
Synergistic Anti-Tumor Effect of Combining Selective CDK7 and BRD4 Inhibition in Neuroblastoma
Gao, Y., Volegova, M. P., Nasholm, N. M., Das, S., Kwiatkowski, N. P., Abraham, B. J., Zhang, T., Gray, N. S., Gustafson, C., Krajewska, M., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.773186 · Cited by 25
Self-citationCyclin‐dependent kinase 7 inhibitor THZ1 in cancer therapy
Li, B., Wang, B., Zhu, C., Tang, D., Pang, J., Zhao, J., Sun, C., Qiu, M., & Qian, Z. (2019) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2019.08.006 · Cited by 23
Induction of BRCAness in Triple-Negative Breast Cancer by a CDK12/13 Inhibitor Improves Chemotherapy
Hopkins, J. L., & Zou, L. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.012 · Cited by 25
Covalent Kinase Inhibitors: An Overview
Gehringer, M. (2020) · Topics in medicinal chemistry · doi:10.1007/7355_2020_103 · Cited by 24
Ketley, A., Wojciechowska, M., Ghidelli, S., Bamborough, P., Ghosh, T. K., López-Morató, M., Sedehizadeh, S., Malik, N. A., Tang, Z., Powalowska, P. K., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz2415 · Cited by 22
An Overview of CDK Enzyme Inhibitors in Cancer Therapy
Mounika, P., Gurupadayya, B., Kumar, H. Y., & Bannimath, N. (2023) · Current Cancer Drug Targets · doi:10.2174/1568009623666230320144713 · Cited by 23
Dutysheva, E. A., Utepova, I. A., Trestsova, M. A., Anisimov, A. S., Чарушин, В. Н., Чупахин, О. Н., Margulis, B. A., Guzhova, I. V., & Lazarev, V. F. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113577 · Cited by 21
Yang, Y., Liao, J., Pan, Z., Meng, J., Zhang, L., Shi, W., Wang, X., Zhang, X., Zhou, Z., Luo, J., et al. (2024) · Advanced Science · doi:10.1002/advs.202413103 · Cited by 22
Inflammatory Immune-Associated eRNA: Mechanisms, Functions and Therapeutic Prospects
Wan, L., Li, W., Meng, Y., Hou, Y., Chen, M., & Xu, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.849451 · Cited by 20
SETD1A regulates transcriptional pause release of heme biosynthesis genes in leukemia
Hoshii, T., Perlee, S. C., Kikuchi, S., Rahmutulla, B., Fukuyo, M., Masuda, T., Ohtsuki, S., Soga, T., Nabet, B., & Kaneda, A. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111727 · Cited by 18
Coming of Age: Targeting Cyclin K in Cancers
Xiao, Y., & Dong, J. (2023) · Cells · doi:10.3390/cells12162044 · Cited by 19
Ang, H. X., Sutiman, N., Deng, X., Liu, A., Cerda-Smith, C. G., Hutchinson, H. M., Kim, H., Bartelt, L. C., Chen, Q., Barrera, A., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2221448120 · Cited by 18
The reversible inhibitor SR-4835 binds Cdk12/cyclin K in a noncanonical G-loop conformation
Schmitz, M., Kaltheuner, I. H., Anand, K., Düster, R., Moecking, J., Monastyrskyi, A., Duckett, D. R., Roush, W. R., & Geyer, M. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105501 · Cited by 20
Self-citationPeuget, S., Zhu, J., Sanz, G., Singh, M., Gaetani, M., Chen, X., Shi, Y., Saei, A. A., Visnes, T., Lindström, M. S., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2069 · Cited by 17
Rational Design of CDK12/13 and BRD4 Molecular Glue Degraders
Zhuang, Z., Byun, W. S., Kozicka, Z., Donovan, K. A., Dwyer, B. G., Thornhill, A. M., Jones, H. M., Jiang, Z., Zhu, X., Fischer, E. S., et al. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202508427 · Cited by 17
Self-citationPitolli, C., Marini, A., Guerra, M., Pieraccioli, M., Marabitti, V., Palluzzi, F., Giacò, L., Tamburrini, G., Cecconi, F., Nazio, F., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02790-2 · Cited by 17
Frei, K., Schecher, S., Daher, T., Hörner, N., Richter, J., Hildebrand, U., Schindeldecker, M., Witzel, H. R., Tsaur, I., Porubský, Š., et al. (2023) · International Journal of Cancer · doi:10.1002/ijc.34778 · Cited by 17
Lu, H., Sun, D., Wang, Z., Cui, H., Min, L., Zhang, H., Zhang, Y., Wu, J., Cai, X., Ding, X., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01616 · Cited by 17
Żuryń, A., Krajewski, A., Klimaszewska‐Wiśniewska, A., Grzanka, A., & Grzanka, D. (2018) · Oncology Reports · doi:10.3892/or.2018.6919 · Cited by 18
Electrophilic Signaling: The Role of Reactive Carbonyl Compounds
Kosmachevskaya, O. V., Шумаев, К. Б., & Topunov, A. F. (2019) · Biochemistry (Moscow) · doi:10.1134/s0006297919140128 · Cited by 17
Chai, Q., Li, S., Collins, M. K., Li, R., Ahmad, I., Johnson, S. F., Frabutt, D. A., Yang, Z., Shen, X., Sun, L., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109514 · Cited by 20
CDK12 Promotes Cervical Cancer Progression through Enhancing Macrophage Infiltration
Yang, B., Chen, J., & Teng, Y. (2021) · Journal of Immunology Research · doi:10.1155/2021/6645885 · Cited by 17
CDK13-Mediated Cell Cycle Disorder Promotes Tumorigenesis of High HMGA2 Expression Gastric Cancer
Wu, Z., Wang, M., Li, F., Wang, F., Jia, J., Feng, Z., Huo, X., Yang, J., Wen, J., Sa, R., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.707295 · Cited by 16
van der Noord, V. E., van de Water, B., & Dévédec, S. E. L. (2022) · Cancers · doi:10.3390/cancers14184353 · Cited by 19
Uehara, T., Takenouchi, T., Kosaki, R., Kurosawa, K., Mizuno, S., & Kosaki, K. (2017) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2017.12.004 · Cited by 17
Yang, J., Chang, Y., Zhou, K., Huang, W., Tien, J. C.-Y., Zhang, P., Liu, W., Zhou, L., Zhou, Y., Ren, X., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00127 · Cited by 15
Chen, P., Sun, J., Zhu, C., Tang, G., Wang, W., Xu, M., Xiang, M., Zhang, C., Zhang, Z., Gao, L., et al. (2022) · Angewandte Chemie · doi:10.1002/ange.202203878 · Cited by 15
Transcription-associated cyclin-dependent kinase 12 (CDK12) as a potential target for cancer therapy
Wu, W., Yu, S., & Yu, X. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188842 · Cited by 16
Kartha, N., Gianopulos, J. E., Schrank, Z., Cavender, S. M., Dobersch, S., Kynnap, B. D., Wallace-Povirk, A., Wladyka, C. L., Santana, J. F., Kim, J. C., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abn9674 · Cited by 15
van der Noord, V. E., van der Stel, W., Louwerens, G., Verhoeven, D., Kuiken, H. J., Lieftink, C., Grandits, M., Ecker, G. F., Beijersbergen, R. L., Bouwman, P., et al. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01648-x · Cited by 15
Targeting cyclin-dependent kinases: From pocket specificity to drug selectivity
Huang, Y., Liu, W., Zhao, C., Shi, X., Zhao, Q., Jia, J., & Wang, A. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116547 · Cited by 19
Super-Enhancers in the Regulation of Gene Transcription: General Aspects and Antitumor Targets
Bruter, A. V., Rodionova, M. D., Varlamova, E. A., & Shtil, A. A. (2021) · Acta Naturae · doi:10.32607/actanaturae.11067 · Cited by 14
Rao, Z., Li, K., Hong, J.-E., Chen, D., Ding, B., Li, J., Qi, X., Hu, J., Yang, B., He, Q., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115248 · Cited by 15
Potential roles of super enhancers in inflammatory gene transcription
Higashijima, Y., & Kanki, Y. (2021) · FEBS Journal · doi:10.1111/febs.16089 · Cited by 14
Metadata
- Authors
- Zhang, T., Kwiatkowski, N., Olson, C. M., Dixon-Clarke, S. E., Abraham, B. J., Greifenberg, A. K., Ficarro, S. B., Elkins, J. M., Liang, Y., Hannett, N. M., Manz, T., Hao, M., Bartkowiak, B., Greenleaf, A. L., Marto, J. A., Geyer, M., Bullock, A. N., Young, R. A., & Gray, N. S.
- Affiliations
- Harvard University (US)
- University of Oxford (GB)
- Whitehead Institute for Biomedical Research (US)
- University of Bonn (DE)
- Dana-Farber Cancer Institute (US)
- Duke Medical Center (US)
- Corresponding author
- Young, Richard A
- Gray, Nathanael S
- ORCID
- Venue
- Nature Chemical Biology
- Published
- 2016-08-29
- Volume
- 12
- Issue
- 10
- Pages
- 876-884
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- PMC
- PMC5033074
- OpenAlex
- W2512442926
- Semantic Scholar
- c8164ef9df7e4d3d418a7b07384190780d6ae6a3
- Cited by
- 374
- References
- 59
- Citations by year
- 2026: 39 · 2025: 35 · 2024: 50 · 2023: 44 · 2022: 40 · 2021: 49 · 2020: 38 · 2019: 27 · 2018: 21 · 2017: 27 · 2016: 4
- FWCI
- 13.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Chemical Biology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- Max Planck Digital Library (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- PMC
- Funders
- Eli Lilly and Company
- Pfizer
- GlaxoSmithKline
- Dana-Farber/Harvard Cancer Center
- Genome Canada (OGI-055)
- Wellcome Trust (106169/Z/14/Z, 092809, 106169, 092809/Z/10/Z, 1097737)
- Diamond Light Source (mx8421, 1097737)
- Ontario Genomics
- Hope Funds for Cancer Research
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- Ontario Genomics Institute (OGI-055, 092809/Z/10/Z)
- Ontario Ministry of Economic Development and Innovation (092809/Z/10/Z)
- Deutsche Forschungsgemeinschaft (GE 976/9-1)
- Ministero dello Sviluppo Economico
- National Institutes of Health (CA109901, CA179483)
- Medical Research Council
- National Human Genome Research Institute (R01HG002668)
- National Cancer Institute (R01CA179483, P01CA109901, P30CA014051)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- CDK12, CDK13, covalent inhibitors, cyclin K, RNA polymerase II processivity, super-enhancers, DNA damage response genes, transcription factor expression, apoptosis, kinase inhibitors
- MeSH terms
- Anilides, Cysteine, DNA Damage, Humans, Pyrimidines, CDC2 Protein Kinase, Cell Death, Cyclin-Dependent Kinases, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
